Trenbolone Enanthate

Package leaflet (information for patients)

Tradename
Trenbolone Enanthate

Dosage form
Solution for injection 200 mg / ml

Description
Transparent liquid of light yellow color with a weak odor.

Structure
1 ml of solution contains:
Active ingredient: Trenbolone Enanthate 200mg.
Auxiliary components: ethyl oleate.

Pharmacotherapeutic group
Anabolic / androgenic steroids.

Pharmacological properties
Trenbolone has both anabolic and androgenic effects. After metabolism, trenbolone esters increase the absorption of ammonium ions by the muscles, which leads to an increase in the rate of protein synthesis. It can also have the side effects of stimulating appetite and reducing the rate of catabolism, as all anabolic steroids are believed to be ; however, catabolism is likely to increase significantly after steroid discontinuation. [8] At least one rat study has shown that trenbolone induces expression of the androgen receptor (AR) gene at least as potently as idihydrotestosterone (DHT). These data indicate that trenbolone can induce an increase in secondary sex characteristics in men without the need to be converted to a more potent androgen in the body.
Metabolic studies are mixed: some studies indicate that it is metabolized by aromatase or 5α- reductase to estrogenic compounds or to 5α-reduced androgenic compounds, respectively.
Trenbolone is five times higher than testosterone. Trenbolone also binds with high affinity to the progesterone receptor; Trenbolone also binds to the glucocorticoid receptor.
Pharmacokinetics
To prolong the half-life of trenbolone, it is administered in the form of a prodrug in the form of a conjugate of an ester, such as trenbolone acetate, trenbolone enanthate or trenbo Lawn Hexahydrobenzylcarbonate. Plasma lipases then break down the ester group in the bloodstream, leaving free trenbolone.
Trenbolone and 17-epitrenbolone are excreted in the urine in the form of conjugates that can be hydrolyzed by beta- glucuronidase. This means that trenbolone leaves the body in the form of beta- glucuronides or sulfates.

Indications for use
Loss of muscle mass after surgery, prolonged infections, serious illness, overdose of corticosteroid drugs, or during recovery. Sarcopenia (natural age-related loss of muscle mass), some cases of chronic hepatitis and breast cancer (mainly as an adjunct to other treatments); increased muscle growth in underweight premature infants and children in clinical cases.

Method of administration and dosage
Please consult your healthcare professional or pharmacist, and read the information on the product packaging.
In case of loss of muscle mass after surgery, prolonged infections, serious illness, overdose of corticosteroid drugs or during the recovery period, this drug must be taken at a dosage of 100-200 mg per week

Side effects
Trenbolone, like any other AAS, has many side effects. Trenbolone's strong androgenic nature contributes to its virilizing tendencies, so it is not recommended for women for physique or performance enhancements. The side effects of Trenbolone are similar to those of other AAS; however, the negative side effects, which are especially promoted by
Trenbolone are as follows. Androgenic Trenbolone is androgenic. Specific to the androgenic properties of Trenbolone, common side effects of using AAS include oily skin, acne, seborrhea, increased facial / body hair growth, and accelerated scalp hair loss. These side effects are highly dependent on a person's genetics and may not always occur in every person. Men who are predisposed to a condition associated with hair loss such as baldness are more likely to become permanently bald after taking Trenbolone. Women may experience decreased voice, hirsutism, enlarged clitoris and virilization in general. Hypogonadism Trenbolone significantly increases muscle mass and feed efficiency; however, the introduction of AAS suppresses the natural production of testosterone; those. it can cause hypogonadism. This is the overall effect of all AAS; the only difference is how much they are suppressive compared to others. Cardiovascular The use of any AAS can lead to cardiovascular disease. Trenbolone can have a negative and powerful effect on cholesterol by suppressing both high-density lipoprotein (HDL) cholesterol (“good” cholesterol) and raising low-density lipoprotein (LDL) cholesterol (“bad” cholesterol). Compared to oral AAS, Trenbolone has a stronger negative effect on cholesterol levels. This negative effect is much stronger when using injectable AAS, especially Trenbolone. "Tren cough" The exact mechanisms underlying the cause of the tren cough are unknown. However, the androgenic effect of Trenbolone activates various lipid-like active compounds called prostaglandins. Many of these prostaglandins are inflammatory and vasoconstrictor. Prostagland signals are transmitted in two different ways: cyclooxygenase (COX) (also known as prostaglandin endoperoxid synthase ) and lipoxygenase (LOX) (also known as: EC 1.13.11.34, EC 1.13.11.33, etc.). The vasoconstriction of the muscular wall of the bronchi in the lungs causes this cough reaction. Trenbolone increases levels of an inflammatory mediator peptide called bradykinin, which helps dilate blood vessels. It is well known that the bradykinin peptide promotes the cough response associated with ACE inhibitor drugs prescribed for hypertension. Estrogenic and Progestogenic No form of Trenbolone, including Trenbolone, is estrogenic. Excessive fluid retention is not possible with this AAS, as it does not have the estrogenic effect of testosterone. However, due to the strong progestogenic activity of Trenbolone, gynecomastia, which is characterized by the development and swelling of breast tissue, is still possible. Stimulation of estrogenic mechanisms is provided by progestogenic activity, since Trenbolone and its compounds bind with high affinity to the progesterone receptor. It has been suggested that the gynecomastia resulting from Trenbolone is due to the accumulation of the hormone prolactin; however, many studies have concluded that this is the progestogenic activity of Trenbolone, not prolactin. Trenbolone also negatively affects blood pressure, but does not appear to have the same negative effects in most healthy adult men.

Contraindication
Hypersensitivity to Trenbolone is a contraindication.
Trenbolone is contraindicated in individuals with chronic liver and kidney disease.
With reasonable dosages and the correct duration of cycles, the drug is practically harmless and does not affect internal organs.

Overdose
Symptoms: hepatotoxicity and intoxication. During intoxication, sweating, nausea, and vomiting may occur. These symptoms can be eliminated by reducing the dose.
Treatment: in case of signs of poisoning, induce vomiting or gastric lavage, prescribe activated charcoal and a laxative, and consult a doctor.
Intoxication and hepatotoxicity are more likely in elderly patients and especially in young children (therapeutic overdose or accidental intoxication can be very dangerous for them).

Precautions
Before taking this drug, tell your doctor about any medications you are using, dietary supplements (such as vitamins, natural supplements, etc.), allergies, existing medical conditions, and current health conditions (such as pregnancy, surgery, etc.). The side effects of the drug may be more pronounced depending on the condition of your body. Take this medicine as directed by your doctor or follow the directions for use that came with the medicine. The dosage of the drug depends on your condition. Tell your doctor if there is no change or worsening of your condition. Important points to discuss with your healthcare provider are listed below.
Pregnancy
Lactation

Interaction with other medicinal products
If you take other drugs or supplements at the same time as this drug, the effectiveness of Trenbolone may change. Tell your healthcare provider about all drugs, vitamins, and supplements you use. Your doctor will be able to make the right dosing plan to avoid negative interactions.

Special instructions
Peliosis of hepatitis can occur in patients receiving anabolic steroids. These cysts may be present with minimal liver dysfunction, but they are associated with a liver defect. Symptoms are often not recognized until a life-threatening liver problem or intra-abdominal bleeding develops. Discontinuation of anabolic steroid treatment usually leads to complete disappearance of the lesions. Tumors in liver cells have also been reported. Many of these tumors are benign and estrogen dependent, but fatal malignant tumors have also been reported; discontinuation of the drug may lead to regression or cessation of tumor development. Even though androgen-related or anabolic steroid-related liver tumors, they are much more vascular than other liver tumors and may not manifest until life-threatening intra-abdominal hemorrhage develops. Changes in blood lipids associated with an increased risk of arteriosclerosis in patients taking androgens and anabolic steroids. These changes include a decrease in high density lipoprotein changes and sometimes an increase in low density lipoprotein. The changes can be very noticeable and should seriously affect the risk of changes in blood lipids associated with an increased risk of arteriosclerosis in patients taking androgens and anabolic steroids

Pregnancy and elbowing
This drug should not be used during pregnancy and lactation.
During pregnancy, the drug can cause virilization in female fetuses.
During breastfeeding, it is not known how anabolic steroids are excreted in breast milk. In accordance with the adverse reactions that may occur in infants, it is necessary to decide whether to stop breastfeeding or stop taking the drug.

Influence on the ability to drive vehicles and work with mechanisms
Does not affect.

Storage conditions
Store in a dry, dark place at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life
3 years. Do not use after the expiration date printed on the package.

Vacation conditions
On prescription.

Packaging
The solution is in 1 ml glass ampoules. Each ampoule is fixed in a plastic clip for 5 ampoules. 5 ampoules are packed in a cardboard box in a fixer together with an enclosed leaflet.